- Home
- KROS vs NGD Comparison
KROS vs NGD Comparison
Compare KROS & NGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- NGD
- Stock Information
- Founded
- KROS 2015
- NGD N/A
- Country
- KROS United States
- NGD Canada
- Employees
- KROS N/A
- NGD N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- NGD
- Sector
- KROS Health Care
- NGD
- Exchange
- KROS Nasdaq
- NGD Nasdaq
- Market Cap
- KROS 1.8B
- NGD 2.0B
- IPO Year
- KROS 2020
- NGD 2004
- Fundamental
- Price
- KROS $56.62
- NGD $2.55
- Analyst Decision
- KROS Strong Buy
- NGD Buy
- Analyst Count
- KROS 8
- NGD 4
- Target Price
- KROS $91.43
- NGD $3.04
- AVG Volume (30 Days)
- KROS 383.1K
- NGD 10.6M
- Earning Date
- KROS 11-06-2024
- NGD 10-29-2024
- Dividend Yield
- KROS N/A
- NGD N/A
- EPS Growth
- KROS N/A
- NGD N/A
- EPS
- KROS N/A
- NGD 0.02
- Revenue
- KROS $651,000.00
- NGD $861,500,000.00
- Revenue This Year
- KROS $1,232.45
- NGD $23.45
- Revenue Next Year
- KROS $126.39
- NGD $24.93
- P/E Ratio
- KROS N/A
- NGD $99.79
- Revenue Growth
- KROS 8037.50
- NGD 14.85
- 52 Week Low
- KROS $27.31
- NGD $1.09
- 52 Week High
- KROS $73.00
- NGD $3.25
- Technical
- Relative Strength Index (RSI)
- KROS 38.94
- NGD 38.35
- Support Level
- KROS $65.54
- NGD $2.44
- Resistance Level
- KROS $70.26
- NGD $2.60
- Average True Range (ATR)
- KROS 3.17
- NGD 0.14
- MACD
- KROS -0.64
- NGD -0.03
- Stochastic Oscillator
- KROS 9.07
- NGD 19.63
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.